Background/Aims: Glomerular filtration rate (GFR) is the best index for evaluating renal function. We aimed to develop a simplified iohexol plasma clearance procedure for GFR measurement in rats without urine collection, animal catheterization or anesthesia, with limited sampling and requiring blood instead of plasma, to further reduce the sample volume and improve animal welfare. Methods: After iohexol injection (129.4 mg), samples were drawn according to 2-compartment kinetics and analyzed by high performance liquid chromatography. Healthy male Lewis rats were used to find a correction factor (CF) to obtain the ‘reference clearance' from the simplified 1-comparment model. This approach was validated using male or female (Lewis, Sprague-Dawley) rats and animals with renal mass reduction (RMR). In additional rats, different simplified approaches were evaluated. Results: Iohexol concentrations in blood and plasma strongly correlated (r = 0.9784, p < 0.0001). A CF of 0.90 enabled the calculation of the reference GFR. Validation results in male Lewis rats were 0.99 ± 0.27 for the reference GFR and 1.03 ± 0.29 ml/min/100 g for the simplified approach. Results in female Sprague-Dawley rats confirmed the suitability of the proposed method. In RMR rats, GFR was 0.14 ± 0.05 and 0.14 ± 0.04 ml/min/100 g for the reference and simplified model, respectively. Conclusion: The procedure we set up to measure GFR in conscious rats was proven to be reliable, required a small volume of blood at only 4 selected time points, without the need to collect urine or catheterize the animals, was applicable to rats from different strains and sexes, both healthy and with renal function impairment. Moreover, the procedure enables the monitoring of GFR changes over time in the same animal, thereby reducing the number of animals to be used.

Keywords:
Conscious rat, Glomerular filtration rate, Iohexol plasma clearance
1.
Darling IM, Morris ME: Evaluation of ‘true' creatinine clearance in rats reveals extensive renal secretion. Pharm Res 1991;8:1318-1322.
2.
Corna D, Sangalli F, Cattaneo D, Carrara F, Gaspari F, Remuzzi A, Zoja C, Benigni A, Perico N, Remuzzi G: Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation. Am J Nephrol 2007;27:630-638.
3.
Sangalli F, Carrara F, Gaspari F, Corna D, Zoja C, Botti L, Remuzzi G, Remuzzi A: Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model. Am J Physiol Renal Physiol 2011;300:F1291-F1300.
4.
Fleck C: Determination of the glomerular filtration rate (GFR): methodological problems, age-dependence, consequences of various surgical interventions, and the influence of different drugs and toxic substances. Physiol Res 1999;48:267-279.
5.
Frennby B, Sterner G, Almén T, Hagstam KE, Hultberg B, Jacobsson L: The use of iohexol clearance to determine GFR in patients with severe chronic renal failure - a comparison between different clearance techniques. Clin Nephrol 1995;43:35-46.
6.
Dalton RN: Serum creatinine and glomerular filtration rate: perception and reality. Clin Chem 2010;56:687-689.
7.
Eisner C, Faulhaber-Walter R, Wang Y, Leelahavanichkul A, Yuen PS, Mizel D, Star RA, Briggs JP, Levine M, Schnermann J: Major contribution of tubular secretion to creatinine clearance in mice. Kidney Int 2010;77:519-526.
8.
Gaspari F, Perico N, Matalone M, Signorini O, Azzollini N, Mister M, Remuzzi G: Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol 1998;9:310-313.
9.
Gaspari F, Guerini E, Perico N, Mosconi L, Ruggenenti P, Remuzzi G: Glomerular filtration rate determined from a single plasma sample after intravenous iohexol injection: is it reliable? J Am Soc Nephrol 1996;7:2689-2693.
10.
Sterner G, Frennby B, Hultberg B, Almen T: Iohexol clearance for GFR-determination in renal failure - single or multiple plasma sampling? Nephrol Dial Transplant 1996;11:521-525.
11.
Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G: Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 1995;6:257-263.
12.
Krutzén E, Bäck SE, Nilsson-Ehle I, Nilsson-Ehle P: Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med 1984;104:955-961.
13.
Brown SC, O'Reilly PH: Iohexol clearance for the determination of glomerular filtration rate in clinical practice: evidence for a new gold standard. J Urol 1991;146:675-679.
14.
Passos MT, Nishida SK, Câmara NO, Shimizu MH, Mastroianni-Kirsztajn G: Iohexol clearance for determination of glomerular filtration rate in rats induced to acute renal failure. PLoS One 2015;10:e0123753.
15.
Krutzén E, Bäck SE, Nilsson-Ehle P: Determination of glomerular filtration rate using iohexol clearance and capillary sampling. Scand J Clin Lab Invest 1990;50:279-283.
16.
Niculescu-Duvaz I, D'Mello L, Maan Z, Barron JL, Newman DJ, Dockrell ME, Kwan JT: Development of an outpatient finger-prick glomerular filtration rate procedure suitable for epidemiological studies. Kidney Int 2006;69:1272-1275.
17.
Bröchner-Mortensen J: A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972;30:271-274.
18.
Jacobsson L: A method for the calculation of renal clearance based on a single plasma sample. Clin Physiol 1983;3:297-305.
19.
Katayama R, Yamaguchi N, Yamashita T, Watanabe S, Satoh H, Yamagishi N, Furuhama K: Calculation of glomerular filtration rate in conscious rats by the use of a bolus injection of iodixanol and a single blood sample. J Pharmacol Toxicol Methods 2010;61:59-64.
20.
Mercatello A: [Changes in renal function induced by anesthesia]. Ann Fr Anesth Reanim 1990;9:507-524.
21.
Schulz A, Boeringer F, Swifka J, Kretschmer A, Schaefer M, Jankowski V, van der Giet M, Schuchardt M, Toelle M, Tepel M, Schlieper G, Zidek W, Jankowski J: A highly sensitive method for quantification of iohexol. Anal Methods 2014;6:3706-3712.
22.
Cağlar Y, Mete UO, Kaya M: Ultrastructural evaluation of the effects of the contrast media on the rat kidney. J Submicrosc Cytol Pathol 2001;33:443-451.
23.
Rodríguez-Romero V, González-Villalva KI, Reyes JL, Franco-Bourland RE, Guízar-Sahagún G, Castañeda-Hernández G, Cruz-Antonio L: A novel, simple and inexpensive procedure for the simultaneous determination of iopamidol and p-aminohippuric acid for renal function assessment from plasma samples in awake rats. J Pharm Biomed Anal 2015;107:196-203.
24.
Jobin J, Bonjour JP: Measurement of glomerular filtration rate in conscious unrestrained rats with inulin infused by implanted osmotic pumps. Am J Physiol 1985;248(5 pt 2):F734-F738.
25.
Fischer PA, Bogoliuk CB, Ramirez AJ, Sánchez RA, Masnatta LD: A new procedure for evaluation of renal function without urine collection in rat. Kidney Int 2000;58:1336-1341.
26.
Pill J, Issaeva O, Woderer S, Sadick M, Kränzlin B, Fiedler F, Klötzer HM, Krämer U, Gretz N: Pharmacological profile and toxicity of fluorescein-labelled sinistrin, a novel marker for GFR measurements. Naunyn Schmiedebergs Arch Pharmacol 2006;373:204-211.
27.
Pill J, Kraenzlin B, Jander J, Sattelkau T, Sadick M, Kloetzer HM, Deus C, Kraemer U, Gretz N: Fluorescein-labeled sinistrin as marker of glomerular filtration rate. Eur J Med Chem 2005;40:1056-1061.
28.
Schock-Kusch D, Sadick M, Henninger N, Kraenzlin B, Claus G, Kloetzer HM, Weiss C, Pill J, Gretz N: Transcutaneous measurement of glomerular filtration rate using FITC-sinistrin in rats. Nephrol Dial Transplant 2009;24:2997-3001.
29.
Chinen LK, Galen KP, Kuan KT, Dyszlewski ME, Ozaki H, Sawai H, Pandurangi RS, Jacobs FG, Dorshow RB, Rajagopalan R: Fluorescence-enhanced europium-diethylenetriaminepentaacetic (DTPA)-monoamide complexes for the assessment of renal function. J Med Chem 2008;51:957-962.
30.
Pill J, Kloetzer HM, Issaeva O, Kraenzlin B, Deus C, Kraemer U, Sadick M, Fiedler F, Gretz N: Direct fluorometric analysis of a newly synthesised fluorescein-labelled marker for glomerular filtration rate. Anal Bioanal Chem 2005;382:59-64.
31.
Rieg T: A high-throughput method for measurement of glomerular filtration rate in conscious mice. J Vis Exp 2013;75:e50330.
32.
Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris RC, Fogo AB, Breyer MD: Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 2004;286:F590-F596.
33.
Sadick M, Attenberger U, Kraenzlin B, Kayed H, Schoenberg SO, Gretz N, Schock-Kusch D: Two non-invasive GFR-estimation methods in rat models of polycystic kidney disease: 3.0 tesla dynamic contrast-enhanced MRI and optical imaging. Nephrol Dial Transplant 2011;26:3101-3108.
34.
Baumann D, Rudin M: Quantitative assessment of rat kidney function by measuring the clearance of the contrast agent Gd(DOTA) using dynamic MRI. Magn Reson Imaging 2000;18:587-595.
35.
Zöllner FG, Schock-Kusch D, Bäcker S, Neudecker S, Gretz N, Schad LR: Simultaneous measurement of kidney function by dynamic contrast enhanced MRI and FITC-sinistrin clearance in rats at 3 tesla: initial results. PLoS One 2013;8:e79992.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.